Escitalopram 10mg
Sponsors
Massachusetts General Hospital, Laboratório Catarinense SA, Wake Forest University Health Sciences, Johns Hopkins University, Tanta University
Conditions
AnxietyApathyAphasiaAutism Spectrum DisorderBurning Mouth SyndromeDepressionEffort Based Decision MakingEpilepsy
Phase 1
Phase 2
Phase 3
Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode
TerminatedNCT02532660
Start: 2018-07-02End: 2022-06-01Updated: 2022-06-16
Role of Nitazoxanide and Escitalopram in Patients With Rheumatoid Arthritis
CompletedNCT05480878
Start: 2022-12-02End: 2023-04-01Updated: 2023-04-25
Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome
NCT06025474
Start: 2023-01-01End: 2024-07-24Target: 203Updated: 2023-09-06
Phase 4
Neurobiological Bases of Placebo Response in Major Depressive Disorder
TerminatedNCT01787240
Start: 2012-11-30End: 2016-08-31Updated: 2017-05-16
Anxiety and Depression in Epilepsy: A Treatment Study
CompletedNCT03464383
Start: 2018-05-07End: 2019-09-20Updated: 2020-10-19
Anxiety and Depression in Epilepsy: A Pilot Treatment Study
WithdrawnNCT03522987
Start: 2018-05-31End: 2018-05-31Updated: 2019-09-12